1. Academic Validation
  2. Recent advances in pretargeted radioimmunotherapy

Recent advances in pretargeted radioimmunotherapy

  • Curr Med Chem. 2005;12(3):319-38. doi: 10.2174/0929867053363225.
A Gruaz-Guyon 1 O Raguin J Barbet
Affiliations

Affiliation

  • 1 EA 3512, Faculté de Médecine Xavier Bichat, Paris, France. gruaz@bichat.inserm.fr
Abstract

Pretargeted delivery of radionuclides is based upon bispecific immunoconjugates that bind a target tumor antigen and a small molecule carrying the active payload. This strategy is supposed to combine the advantage of Antibodies to track tumor cells in vivo and of small radiolabeled molecules that clear rapidly from normal organs and minimize toxicity. Many pretargeting approaches have been proposed, but only those using the biotin/avidin recognition system and those using bispecific anti-tumor x anti-hapten Antibodies have been tested in the clinic for both immunoscintigraphy and radioimmunotherapy. Their respective advantages and drawbacks, as well as hurdles in the way of an effective therapy against solid tumors, are discussed. In the light of the encouraging results obtained so far in the clinic, pretargeting remains a most promising challenge for chemistry and biotechnology.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》